8 -4 (90) 2026 - Abdukakharova G.K., Ashurov Z.Sh. - CLINICAL AND PROGNOSTIC ASSESSMENT OF RECURRENCE RISK IN PATIENTS WITH ADDICTION TO NEW PSYCHOACTIVE SUBSTANCES

CLINICAL AND PROGNOSTIC ASSESSMENT OF RECURRENCE RISK IN PATIENTS WITH ADDICTION TO NEW PSYCHOACTIVE SUBSTANCES

Abdukakharova G.K. - Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Republic of Uzbekistan

Ashurov Z.Sh. - Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Republic of Uzbekistan

Tadjibaev U.A. - Republican Specialized Scientific and Practical Medical Center for Mental Health, Tashkent, Republic of Uzbekistan

Resume

Dependence on new psychoactive substances (NPS) is associated with high relapse rates and clinical instability, which complicates prediction of disease course. This study evaluates relapse risk in patients with dependence on synthetic cathinones, cannabinoids, and pregabalin based on craving and affective symptoms. A total of 166 patients were examined with a 3-month follow-up. The relapse rate reached 77.1% and increased consistently with risk level, from 46.2% in the low-risk group to 94.6% in the high-risk group. The most unfavorable outcomes were observed in patients with synthetic cathinone dependence. Dynamic changes in craving, anxiety, and mood were found to be clinically relevant predictors of relapse. The findings support the use of dynamic risk assessment for improving treatment and rehabilitation strategies.

Keywords: new psychoactive substances; addiction; relapse; craving; anxiety; depression; prognosis; clinical assessment

First page

51

Last page

57

For citation:Abdukakharova G.K., Ashurov Z.Sh., Tadjibaev U.A. - CLINICAL AND PROGNOSTIC ASSESSMENT OF RECURRENCE RISK IN PATIENTS WITH ADDICTION TO NEW PSYCHOACTIVE SUBSTANCES//New Day in Medicine 4(90)2026 51-57 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

1. Ashurov ZSh, Khayredinova II, Abdukakharova GK, Tadjibaev UA. Changes in the patterns of psychoactive substance use in Uzbekistan: from assessment to preventive measures. Am J Med Med Sci. 2025;15(4):1187–1191. doi:10.5923/j.ajmms.20251504.68
2. Chen S, Zhou W, Lai M. Synthetic cathinones: epidemiology, toxicity, potential for abuse, and public health perspective. Brain Sci. 2024;14(4):334. doi:10.3390/brainsci14040334
3. Lauvsnes ADF, Gråwe RW, Langaas M. Predicting relapse in substance use: prospective modeling based on longitudinal data. Brain Sci. 2022;12(7):957. doi:10.3390/brainsci12070957
4. European Union Drugs Agency. European Drug Report 2025: Trends and Developments. Luxembourg: Publications Office of the European Union; 2025.
5. Neoh MJY, Carollo A, Corazza O, Esposito G. The novel psychoactive substances epidemic: a scientometric perspective. Addict Neurosci. 2023;6:100082. doi:10.1016/j.addictn.2022.100082
6. Shafi A, Berry AJ, Sumnall H, Wood DM, Tracy DK. New psychoactive substances: a review and updates. Ther Adv Psychopharmacol. 2020;10:2045125320967197. doi:10.1177/2045125320967197
7. Schifano F, Napoletano F, Arillotta D, et al. The clinical challenges of synthetic cathinones. Br J Clin Pharmacol. 2020;86(3):410–419. doi:10.1111/bcp.14132
8. United Nations Office on Drugs and Crime. World Drug Report 2024. Vienna: UNODC; 2024.
9. National Institute on Drug Abuse. Drugs, brains, and behavior: the science of addiction. Bethesda (MD): NIDA; 2020.
10. Verdejo-Garcia A, Albein-Urios N. Impulsivity traits and neurocognitive mechanisms in addiction. Neurosci Biobehav Rev. 2021;128:314–329. doi:10.1016/j.neubiorev.2021.06.019

    file

    download